<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":6283,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
In re Schering-Plough Corp. Intron/Temodar Consumer Class Action, 678 F.3d 235 (3d Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/3de4ccbf5d4b435f76622fdd483573fe'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/3de4ccbf5d4b435f76622fdd483573fe'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1HO1HK003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HO1HK003">Previous Result: <span>Wells v. Smith, Civil Action No. 12-cv-0...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1HO1IC003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HO1IC003">Next Result: <span>Cosby v. Johnson, Civil Action No. 12 07...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation distinguished" title="Distinguished"></div>
<div class='title left' title='In re Schering-Plough Corp. Intron/Temodar Consumer Class Action, 678 F.3d 235 (3d Cir. 2012), Court Opinion'>
In re Schering-Plough Corp. Intron/Temodar Consumer Class Action, 678 F.3d 235 (3d Cir. 2012),...
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>In re Schering-Plough Corp. Intron/Temodar Consumer Class Action, 678 F.3d 235 (3d Cir. 2012), Court Opinion</div>
<div class='docId'>X1HO0DG003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>In re Schering-Plough Corp. Intron/Temodar Consumer Class Action</div>
<div class='displayCitation'>2012 BL 121265</div>
<div class='displayCitation'>678 F.3d 235</div>
<div class='displayCitation'>bna a0d1z6h2n5</div>
<div class='displayCitation'>wkf3case:26083544</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HO0DG003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="In re Schering-Plough Corp. Intron/Temodar Consumer Class Action, 678 F.3d 235 (3d Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="In re Schering-Plough Corp. Intron/Temodar Consumer Class Action" />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1HO0DG003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HO0DG003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HO0DG003" /><input id="title" name="title" type="hidden" value="In re Schering-Plough Corp. Intron/Temodar Consumer Class Action, 678 F.3d 235 (3d Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="DISTINGUISHED" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="3de4ccbf5d4b435f76622fdd483573fe" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HO0DG003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="false" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%33de%34ccbf%35d%34b%34%33%35f%37%36%36%32%32fdd%34%38%33%35%37%33fe%2Fdocument%2FX%31HO%30DG%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/bcite/X1HO0DG003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/bcite/X1HO0DG003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/bcite/X1HO0DG003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/related_content/X1HO0DG003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1709411139587";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">678 F.3d 235</div>
<div class="cite" data-cite-type="DocketNumber">Nos. 10-3046, 10-3047.</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 121265</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Third Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
In re SCHERING PLOUGH CORP. INTRON/TEMODAR CONSUMER CLASS ACTION. Angela
Montgomery, Appellant in No. 10-3046. International Brotherhood of Teamsters
Local No. 331 Health &amp; Welfare Trust Fund, Appellant in No. 10-3047.
</center></p>
<hr align="center" width="65%">
<p><center>
Nos. 10-3046, 10-3047.
</center></p>
<p><center>
Argued December 15, 2011.
</center></p>
<p><center>
Filed: May 16, 2012.
</center></p>
<div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the District of New Jersey,
Stanley R. Chesler, J.
<span CLASS="page_no" data-cite="678 f 3d 236" data-cite-type="PrimaryFederalReporter" data-cite-pageno="236" data-primary-citation="678 F.3d 235">[*236]</span> 
[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span CLASS="page_no" data-cite="678 f 3d 237" data-cite-type="PrimaryFederalReporter" data-cite-pageno="237" data-primary-citation="678 F.3d 235">[*237]</span> 
[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
</p></div>
<span CLASS="page_no" data-cite="678 f 3d 238" data-cite-type="PrimaryFederalReporter" data-cite-pageno="238" data-primary-citation="678 F.3d 235">[*238]</span> <div id="para2" printdualcolumn="true"><p>
Donald E. Haviland, Jr., Esq. (Argued), Michael J. Lorusso, Esq., Haviland
Hughes, Philadelphia, PA, for Plaintiff-Appellant Angela Montgomery.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Stephen G. Grygiel, Esq. (Argued), John E. Keefe, Jr., Esq., Stephen T.
Sullivan, Jr., Esq., Keefe Bartels, Red Bank, NJ, for Plaintiff-Appellant
International Brotherhood of Teamsters Local No. 331 Health &amp; Welfare Trust
Fund.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Douglas S. Eakeley, Esq., Natalie J. Kraner, Esq., Alan S. Modlinger, Esq.,
Kristin A. Muir, Esq., Gavin J. Rooney, Esq. (Argued), Lowenstein Sandler,
Roseland, NJ, for Defendant-Appellee Schering Plough Corp.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before: SLOVITER, VANASKIE and GREENBERG, Circuit Judges.
</p></div>
<div id="contentOpinion" printdualcolumn="true"><div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  OPINION
</p></div></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  VANASKIE, Circuit Judge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At issue in these consolidated appeals is the standing of third-party
payors of drugs prescribed for "off-label" purposes, <i>i.e.</i>, uses not approved
by the Food and Drug Administration ("FDA"), as well as the standing of
individual patients prescribed drugs for off-label purposes, to pursue
claims against a pharmaceutical company and its affiliated marketing
entities under the Racketeer Influenced and Corrupt Organizations Act
("RICO"), <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEHSS4003?jcsearch=18%20usc%201961&amp;summary=yes#jcite">18 U.S.C. &sect; 1961</a>, <i>et seq.</i>, the New Jersey RICO statute, N.J.S.A. &sect;
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XF76F0003?jcsearch=N.J.S.A.2C:41-1&amp;summary=yes#jcite">2C:41-1</a>, <i>et seq.</i>, as well as other state statutory and common law causes of
action. Both groups of plaintiffs claim that the defendants pursued illegal
marketing campaigns to persuade physicians to prescribe certain drugs for
off-label uses. The District Court found that both groups of plaintiffs
lacked standing because, <i>inter alia</i>, they did not allege a plausible nexus
between the assailed marketing campaign and the physicians' decisions to
prescribe certain drugs for off-label use. Having carefully considered the
<span CLASS="page_no" data-cite="678 f 3d 239" data-cite-type="PrimaryFederalReporter" data-cite-pageno="239" data-primary-citation="678 F.3d 235">[*239]</span> 
parties' contentions in the context of the entire record, we agree that
dismissal of both actions for want of standing is warranted. Accordingly, we
will affirm the District Court's well-reasoned decisions.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>I.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>A. The Parties</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  There are two sets of plaintiffs in these consolidated appeals. One set of
Plaintiffs consists of a putative nationwide class of third-party payors
("TPPs").<a HREF="#fn100" name="fnref_fn100">[fn1]</a> The other set of Plaintiffs is comprised of a putative
nationwide class of individual patient-consumers who paid for prescriptions
of certain drugs for off-label uses, with the named class representative
being Angela F. Montgomery.<a HREF="#fn200" name="fnref_fn200">[fn2]</a> Separate Amended Complaints were filed on
behalf of each set of Plaintiffs. The Defendants common to <span CLASS="page_no" data-cite="2012 bl 121265 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[**2]</span> both Amended
Complaints are the Schering-Plough Corporation, a manufacturer of
pharmaceutical products, and its affiliated marketing and sales companies,
the Schering Sales Corporation and Schering Corporation. The TPP Amended
Complaint also names as defendants another Schering subsidiary, Integrated
Therapeutics Group, Inc., individual Schering executives Richard J. Kogan,
William K. Heiden, and Mary Naughton, as well as unnamed individuals ("John
Doe" and "Jane Doe" defendants), and unknown business entities ("ABC
Corporations"), who purportedly participated in the alleged illegal and
false sales and marketing campaigns. For sake of simplicity, we shall refer
to the Defendants collectively as "Schering." Both sets of Plaintiffs assert
that they paid for Schering drugs that were ineffective or unsafe for the
off-label uses for which they were prescribed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>B. FDCA Labeling and Marketing Regulations</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The off-label marketing claims are at least partially predicated on
Schering's alleged violations of the labeling and marketing restrictions of
the Federal Food, Drug and Cosmetic Act, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEI5LU003?jcsearch=21%20usc%20301&amp;summary=yes#jcite">21 U.S.C. &sect; 301</a><i>et seq.</i> ("FDCA").
The FDCA regulates the manufacturing, marketing and sale of prescription
drugs, and provides that a drug cannot be sold in interstate commerce unless
it is approved by the FDA for the specific medical use, or "indication,"
listed on the drug's labeling. <i>See</i><a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(a) ("No person shall
introduce or deliver for introduction into interstate commerce any new drug,
unless an approval of an application filed pursuant to <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)&amp;summary=yes#jcite">subsection (b)</a> or <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)&amp;summary=yes#jcite">(j)</a>
of this section is effective with respect to such drug."). To obtain FDA
approval, drug companies generally must submit evidence from clinical trials
and other testing that evaluate the drug's risks and benefits and
demonstrate that it is safe and effective for all of the indications
"prescribed, recommended, or suggested" on the drug's label. <i>See <cite>id</cite>.</i> at <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(d)&amp;summary=yes#jcite">&sect;
355(d)</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Prescription drugs frequently have therapeutic uses other than their
FDA-approved indications. The FDCA, however,
<span CLASS="page_no" data-cite="678 f 3d 240" data-cite-type="PrimaryFederalReporter" data-cite-pageno="240" data-primary-citation="678 F.3d 235">[*240]</span> 
generally prohibits manufacturers from marketing, advertising, or otherwise
promoting drugs for such unapproved or "off-label" uses.
<i>See</i><a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a) and <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(d)&amp;summary=yes#jcite">(d)</a> (prohibiting manufacturers from introducing a
drug into interstate commerce with an intent that it be used for an
off-label purchase, or by "misbranding" it by including information about
unapproved uses on its label).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because the FDCA does not regulate the practice of medicine, physicians
may lawfully prescribe drugs for off-label uses. <i>See Buckman Co. v.</i>
<i>Plaintiffs' Legal Comm.</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. 341</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">350</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X4U3HP?jcsearch=148%20l%20ed%202d%20854&amp;summary=yes#jcite">148 L.Ed.2d 854</a>
(2001) (recognizing off-label usage as "an accepted and necessary corollary
of the FDA's mission to regulate in this area without directly interfering
with the practice of medicine."); <i>Wash. Legal Found, v. Henney</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X3IN8E?jcsearch=202%20f%203d%20331&amp;summary=yes#jcite">202 F.3d 331</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X3IN8E?jcsearch=202%20f%203d%20331&amp;summary=yes#jcite">333</a> (D.C.Cir.2000) ("A physician may prescribe a legal drug to
serve any purpose that he or she deems appropriate, regardless of whether
the drug has been approved for that use by the FDA."). Thus, there is a
certain "asymmetry" in the regulation of off-label uses: while physicians
may lawfully prescribe drugs for off-label uses, the FDCA <span CLASS="page_no" data-cite="2012 bl 121265 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[**3]</span> generally
prohibits manufacturers from marketing these uses to physicians. <i>See </i><a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X3IN8E?jcsearch=202%20F.3d%20332&amp;summary=yes#jcite">id. at
332-33</a> (referring to the FDCA's "asymmetrical &mdash; if not necessarily
inconsistent &mdash; regulatory treatment" of off-label uses). Indeed, the FDCA's
regulatory regime prohibits manufacturers from directly advertising
off-label uses, such as through labeling claims or explicit statements made
by sales representatives. Moreover, it is also unlawful for manufacturers to
engage in certain in-direct methods of off-label marketing. For example, in
certain circumstances it is unlawful for manufacturers to sponsor continuing
medical education ("CME") courses that focus on off-label uses. The FDCA
does, however, permit manufacturers to distribute information about
off-label uses in certain limited circumstances. <i>See </i><a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X3IN8E?jcsearch=202%20F.3d%20333&amp;summary=yes#jcite">id. at 333</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The drugs involved in these consolidated appeals (the "Subject Drugs") are
certain oncology and Hepatitis drugs, including Intron&reg;-A ("Intron-A"),
PEG-Intron&reg; ("PEG-Intron"), Rebetol&reg; ("Rebetol") and Rebetron&reg; ("Rebetron")
(collectively the "Intron Franchise Drugs"), and Temodar&reg; ("Temodar"). The
FDA has approved these drugs for specific purposes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>C. Criminal Case Against Schering</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In June 2001, the FDA's Division of Drug Marketing, Advertising, and
Communications sent Schering Sales a letter notifying it that the FDA had
"identified various promotional activities that [were] in violation of the
[FDCA] and its implementing regulations." (Information at 12-16, <i>United</i>
<i>States v. Schering Sales Corp.</i>, <cite>No. 06-CR-10250</cite> (D.Mass. Aug. 29, 2006)).
The letter cited a May 2001 American Society of Clinical Oncology Annual
Meeting in San Francisco at which the FDA witnessed Schering sales
representatives give purportedly "false or misleading efficacy information
about Temodar to visitors at the commercial exhibit hall booth," and
"promote[] Temodar for the unapproved use in first line therapy of
anaplastic astrocytoma." (<i></i><cite>Id. at 12-13</cite>). The FDA's letter requested that
Schering "immediately cease making such violative statements and any other
promotional activities or materials for Temodar that make the same or
similar claims or presentations." (<i></i><cite>Id. at 13</cite>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In August 2006, the United States Attorney for the District of
Massachusetts charged Schering Sales with conspiracy to make false
statements to the federal government, in violation of <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEHRNC003?jcsearch=18%20usc%20371&amp;summary=yes#jcite">18 U.S.C. &sect; 371</a>. (<i></i><cite>Id.
at 12-16</cite>). The Government's one-count
<span CLASS="page_no" data-cite="678 f 3d 241" data-cite-type="PrimaryFederalReporter" data-cite-pageno="241" data-primary-citation="678 F.3d 235">[*241]</span> 
Information alleged that "Schering Sales and its co-conspirators knowingly
and willfully made material false statements to the FDA." (<i></i><cite>Id. at 8</cite>). It
stated that Schering Sales' response to the FDA June 2001 letter
specifically asserted that Schering's home office had "aggressively pursued
sales of Intron A and Temodar for unapproved uses" through numerous methods,
including training the sales force to seek off-label sales, requiring the
sales force to "create business plans that emphasized detailed promotional
goals to obtain off-label sales," and compensating the sales force partly on
their success in achieving off-label sales. (<i><cite>Id</cite>.</i>)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Schering Sales pleaded guilty to the one-count Information <span CLASS="page_no" data-cite="2012 bl 121265 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[**4]</span> pursuant to a
written Settlement Agreement. (<i>See</i> Amended Judgment, <i>United States v.</i>
<i>Schering Sales Corp.</i>, <cite>06-CR-10250</cite> (D.Mass. Feb 7, 2007)). Under the
Settlement Agreement, Schering Sales agreed to pay fine of $180 million.
(<i><cite>Id</cite>.</i>) It also agreed to pay $255 million to resolve civil claims that it
defrauded U.S. Government health benefit programs, including Medicare,
Medicaid, and the Veteran's Administration. (<i><cite>Id</cite>.</i>)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>D. Consolidated Putative Class Action</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Following Schering's settlement with the Government, various civil suits
were filed across the country by consumer plaintiffs who were prescribed,
consumed, and paid for the drugs, and by TPPs who paid for the Subject Drugs
prescribed to their plan members. The Judicial Panel on Multi-District
Litigation ordered the cases to be transferred to the District of New
Jersey, where Schering is incorporated, and consolidated pursuant to
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEIN26003?jcsearch=28%20usc%201407&amp;summary=yes#jcite">28 U.S.C. &sect; 1407</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The District Court directed that the various actions transferred to it be
consolidated for pretrial management and that a consolidated complaint on
behalf of all plaintiffs be filed. In December 2007, the nine named
plaintiffs (the four TPPs and five patients identified in footnotes 1 and 2,
<i><cite>supra</cite></i>) filed a Consolidated Class Action Complaint (the "Complaint") on
behalf of themselves and others similarly situated, alleging that the
Defendants engaged in illegal promotion of the Subject Drugs in violation of
the federal and New Jersey RICO statutes (Counts I and II), and the New
Jersey Consumer Fraud Act ("NJCFA"), N.J. Stat. Ann. &sect; <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XCPD08003?jcsearch=N.J.%20Stat.%20Ann.%20%2056:8-1&amp;summary=yes#jcite">56:8-1</a>, <i>et seq.</i>
(Count III). The Complaint also asserted common law claims for unjust
enrichment (Count IV); civil conspiracy (Count V); fraud (Count VI);
negligent misrepresentation (Count VII); aiding and abetting breach of
fiduciary duty (Count VIII); and equitable accounting (Count IX).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In an Order and Opinion issued on July 10, 2009, the District Court
dismissed the Complaint in its entirety pursuant to Fed. R.Civ.P. <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X144L10003?jcsearch=Fed.%20R.%20Civ.%20P.%209(b)&amp;summary=yes#jcite">9</a>(b),
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(1)&amp;summary=yes#jcite">12(b)(1)</a> and <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(6)&amp;summary=yes#jcite">12(b)(6),</a> for failure to state a claim and lack of standing,
but granted leave to file an amended complaint. <i>In re Schering-Plough Corp.</i>
<i>Intron/Temodar Consumer Class Action</i>, Slip Copy, 2009 WL 2043604
(D.N.J.2009) ("<i>Schering I</i>"). The Court found that the Complaint lacked
sufficient factual allegations to plausibly assert an injury-in-fact that
was cognizable under any of the asserted causes of action and fairly
traceable to the Defendants' alleged misconduct.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In September 2009, two separate Amended Complaints were filed, one by
Montgomery and the other by the four TPP plaintiffs identified in footnote
1, <i>supra.</i> Montgomery filed an Amended Civil Consumer Class Action Complaint
("MAC") individually and on behalf of a putative nationwide class of
similarly situated patient-consumers who purchased, were reimbursed, and/or
paid for any of the Subject Drugs during the class period.
<span CLASS="page_no" data-cite="678 f 3d 242" data-cite-type="PrimaryFederalReporter" data-cite-pageno="242" data-primary-citation="678 F.3d 235">[*242]</span> 
The MAC asserted violations of the Washington State Consumer Protection Act,
Wash. Rev.Code &sect; <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XGO5LI003?jcsearch=Wash.%20Rev.%20Code%20%2019.86.010&amp;summary=yes#jcite">19.86.010</a>, <i>et seq.</i> (Count I), and the consumer protection
statutes of the remaining 49 states, the District of Columbia, and Puerto
Rico (Count II), as well as claims of civil conspiracy (Count III), aiding
and <span CLASS="page_no" data-cite="2012 bl 121265 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[**5]</span> abetting breach of fiduciary duty (Count IV), and unjust enrichment
(Count V).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The TPP plaintiffs filed an Amended Consolidated Class Action Complaint
("TPP Complaint") on behalf of a proposed class of health and welfare funds
and other TPPs who paid any portion of the purchase price for the Subject
Drugs during the class period. The TPP Complaint asserted violations of the
federal and New Jersey RICO statutes, (Counts I and II), in addition to
common law claims for intentional interference with contractual relations
(Count III) and unjust enrichment (Count IV).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Plaintiffs' Amended Complaints allege that Schering engaged in a
widespread marketing campaign that employed illegal techniques to promote
prescriptions of the Subject Drugs for off-label uses. They contend that
these illegal practices included: (1) promoting certain of the Subject Drugs
for off-label uses; (2) using false and misleading statements to promote
certain of the Subject Drugs as effective, safe, and cost-effective for
off-label uses; and (3) providing physicians with disguised and undisguised
bribes, kick-backs and other illegal inducements to encourage them to
prescribe the Subject Drugs for off-label uses.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Plaintiffs claim that Schering used a variety of methods to effectuate
this marketing scheme and disseminate its false claims. For example, they
allege that Schering trained its sales representatives to mislead medical
professionals about the Subject Drugs' effectiveness for off-label uses by
distorting contrary scientific data and the results of clinical studies.
They also claim that the Schering sales force promoted off-label
prescriptions by disseminating false and misleading statements in private
sales meetings with doctors, at medical conferences, and in CME programs.
Plaintiffs also assert that Schering promoted these off-label prescriptions
through both disguised and un-disguised bribes to induce doctors to
prescribe the Subject Drugs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Plaintiffs aver that Schering's unlawful marketing practices caused
physicians to prescribe the Subject Drugs for off-label uses instead of
equally effective alternative treatments that were approved for the
prescribed uses or no medication at all. They assert that these marketing
techniques led to a significant increase in prescriptions of the Subject
Drugs for off-label uses, and contend that this caused the Plaintiffs
"ascertainable loss" because they paid "hundreds of millions, if not
billions, of dollars for the Subject Drugs that they otherwise would not
have paid."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On October 28, 2009, Schering filed separate motions to dismiss each
Amended Complaint. On June 9, 2010, the District Court issued separate
Orders and Opinions (collectively, "<i>Schering II</i>") granting both motions. The
Court dismissed the TPP Complaint because it failed to adequately plead the
injury-in-fact and causation elements required to establish standing to
assert its RICO, interference with contractual relations, and unjust
enrichment claims. The Court also held that even if the Complaint <span CLASS="page_no" data-cite="2012 bl 121265 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[**6]</span> had
established standing to pursue non-RICO claims, its two common law claims of
interference with contractual relations and unjust enrichment would still
fail under <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(6)&amp;summary=yes#jcite">Rule 12(b)(6)</a>. The Court dismissed the MAC for failure to show a
causal link between
<span CLASS="page_no" data-cite="678 f 3d 243" data-cite-type="PrimaryFederalReporter" data-cite-pageno="243" data-primary-citation="678 F.3d 235">[*243]</span> 
Montgomery's alleged injury and Schering's alleged misconduct.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>II.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We have jurisdiction over this appeal pursuant to <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEIMU8003?jcsearch=28%20usc%201291&amp;summary=yes#jcite">28 U.S.C. &sect; 1291</a>. We
exercise plenary review over the District Court's dismissal of the Amended
Complaints. <i>See United States ex rel. Atkinson v. Pa. Shipbuilding Co.</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X166416003?jcsearch=473%20f%203d%20506&amp;summary=yes#jcite">473 F.3d 506</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X166416003?jcsearch=473%20f%203d%20506&amp;summary=yes#jcite">514</a> (3d Cir.2007) (review of dismissal for lack of subject
matter jurisdiction under <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(1)&amp;summary=yes#jcite">Rule 12(b)(1)</a> is plenary); <i>Howard Hess Dental</i>
<i>Labs. Inc. v. Dentsply Int'l Inc.</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1D25CM003?jcsearch=602%20f%203d%20237&amp;summary=yes#jcite">602 F.3d 237</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1D25CM003?jcsearch=602%20f%203d%20237&amp;summary=yes#jcite">246</a> (3d Cir.2010) (review
of <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(6)&amp;summary=yes#jcite">Rule 12(b)(6)</a> dismissal is plenary).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under Fed.R.Civ.P. <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(1)&amp;summary=yes#jcite">12</a>(b)(1), a court must grant a motion to dismiss if it
lacks subject-matter jurisdiction to hear a claim. "A motion to dismiss for
want of standing is . . . properly brought pursuant to <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(1)&amp;summary=yes#jcite">Rule 12(b)(1)</a>,
because standing is a jurisdictional matter." <i>Ballentine v. United States</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X16Q1N8003?jcsearch=486%20f%203d%20806&amp;summary=yes#jcite">486 F.3d 806</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X16Q1N8003?jcsearch=486%20f%203d%20806&amp;summary=yes#jcite">810</a> (3d Cir.2007). In evaluating a Rule 12(b)(1) motion, a
court must first determine whether the movant presents a facial or factual
attack. <i>Mortensen v. First Fed. Sav. &amp; Loan Ass'n</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X3OCSE?jcsearch=549%20f%202d%20884&amp;summary=yes#jcite">549 F.2d 884</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X3OCSE?jcsearch=549%20f%202d%20884&amp;summary=yes#jcite">891</a> (3d
Cir.1977). In reviewing a facial challenge, which contests the sufficiency
of the pleadings, "the court must only consider the allegations of the
complaint and documents referenced therein and attached thereto, in the
light most favorable to the plaintiff." <i>Gould Elec. Inc. v. United States</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X3FHLF?jcsearch=220%20f%203d%20169&amp;summary=yes#jcite">220 F.3d 169</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X3FHLF?jcsearch=220%20f%203d%20169&amp;summary=yes#jcite">176</a> (3d Cir.2000). The Defendants' Rule 12(b)(1) motions are
properly understood as facial attacks because they contend that the Amended
Complaints lack sufficient factual allegations to establish standing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In evaluating whether a complaint adequately pleads the elements of
standing, courts apply the standard of reviewing a complaint pursuant to a
Rule 12(b)(6) motion to dismiss for failure to state a claim: "Court[s] must
accept as true all material allegations set forth in the complaint, and must
construe those facts in favor of the nonmoving party." <i>Ballentine</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X16Q1N8003?jcsearch=486%20f%203d%20806&amp;summary=yes#jcite">486 F.3d at 810</a> (citing <i>Worth v. Seldin</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C918?jcsearch=422%20us%20490&amp;summary=yes#jcite">422 U.S. 490</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C918?jcsearch=422%20us%20490&amp;summary=yes#jcite">501</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C918?jcsearch=95%20supreme%20court%202197&amp;summary=yes#jcite">95 S.Ct. 2197</a>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C918?jcsearch=45%20l%20ed%202d%20343&amp;summary=yes#jcite">45 L.Ed.2d 343</a> (1975)); <i>see also Baldwin v. Univ. of Pittsburgh Med. Ctr.</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1F6JH2003?jcsearch=636%20f%203d%2069&amp;summary=yes#jcite">636 F.3d 69</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1F6JH2003?jcsearch=636%20f%203d%2069&amp;summary=yes#jcite">73</a> (3d Cir.2011) ("A dismissal for lack of statutory standing
is effectively the same as a dismissal for failure to state a claim."). The
Supreme Court most recently explained this standard in <i>Bell Atl. Corp. v.</i>
<i>Twombly</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X17292G003?jcsearch=550%20us%20544&amp;summary=yes#jcite">550 U.S. 544</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X17292G003?jcsearch=127%20supreme%20court%201955&amp;summary=yes#jcite">127 S.Ct. 1955</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X17292G003?jcsearch=167%20l%20ed%202d%20929&amp;summary=yes#jcite">167 L.Ed.2d 929</a> (2007), and <i>Ashcroft</i>
<i>v. Iqbal</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1B3QVK003?jcsearch=556%20us%20662&amp;summary=yes#jcite">556 U.S. 662</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1B3QVK003?jcsearch=129%20supreme%20court%201937&amp;summary=yes#jcite">129 S.Ct. 1937</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1B3QVK003?jcsearch=173%20l%20ed%202d%20868&amp;summary=yes#jcite">173 L.Ed.2d 868</a> (2009): "[A]
complaint must contain sufficient factual matter, accepted as true, to
'state a claim to relief that is plausible on its face.'" <i>Iqbal</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/1?citation=129%20supreme%20court%201937&amp;summary=yes#jcite">129 S.Ct. at 1949</a> (quoting <i>Twombly</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X17292G003?jcsearch=550%20us%20544&amp;summary=yes#jcite">550 U.S. at 570</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X17292G003?jcsearch=127%20supreme%20court%201955&amp;summary=yes#jcite">127 S.Ct. 1955</a>). We
have outlined a three-step approach to evaluating whether a complaint
satisfies this standard:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      First, the court must "tak[e] note of the elements a plaintiff
    must plead to state a claim." Second, the court should identify
    allegations that, "because they are no more than conclusions, are
    not entitled to the assumption of truth." Finally, "where there are
    well-pleaded factual allegations, a court should assume their
    veracity and then determine whether they plausibly give rise to an
    entitlement for relief."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Santiago v. Warminster Twp.</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1EN32A003?jcsearch=629%20f%203d%20121&amp;summary=yes#jcite">629 F.3d 121</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1EN32A003?jcsearch=629%20f%203d%20121&amp;summary=yes#jcite">130</a> (3d Cir.2010) (quoting <i>Iqbal</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/1?citation=129%20supreme%20court%201937&amp;summary=yes#jcite">129 S.Ct. at 1947-50</a>) (footnote omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While the plausibility <span CLASS="page_no" data-cite="2012 bl 121265 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[**7]</span> standard does not impose a "probability
requirement," it does demand "more than a sheer possibility that a defendant
has acted unlawfully." <i>Iqbal</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/1?citation=129%20supreme%20court%201937&amp;summary=yes#jcite">129 S.Ct. at 1949</a> (citing <i>Twombly</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X17292G003?jcsearch=550%20us%20544&amp;summary=yes#jcite">550 U.S. at 556</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X17292G003?jcsearch=127%20supreme%20court%201955&amp;summary=yes#jcite">127 S.Ct. 1955</a>). Pursuant to <i>Iqbal's</i> clarification of the
plausibility determination
<span CLASS="page_no" data-cite="678 f 3d 244" data-cite-type="PrimaryFederalReporter" data-cite-pageno="244" data-primary-citation="678 F.3d 235">[*244]</span> 
as a "context-specific task that requires the reviewing court to draw on its
judicial experience and common sense," <i><a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1B3QVK003?jcsearch=129%20S.Ct.%20at%201949&amp;summary=yes#jcite">id</a>.</i>, this Court has found that
"[s]ome claims require more factual explication than others to state a
plausible claim for relief." <i>West Penn Allegheny Health Sys., Inc. v. UPMC</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1EL69I003?jcsearch=627%20f%203d%2085&amp;summary=yes#jcite">627 F.3d 85</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1EL69I003?jcsearch=627%20f%203d%2085&amp;summary=yes#jcite">98</a> (3d Cir.2010). We have reasoned that, "[f]or example, it
generally takes fewer factual allegations to state a claim for simple
battery than to state a claim for antitrust conspiracy." <i><a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1EL69I003?jcsearch=627%20F.3d%2085&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "A complaint has to 'show such an entitlement with its facts." <i>Fowler v.</i>
<i>UPMC Shadyside</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1BGQ68003?jcsearch=578%20f%203d%20203&amp;summary=yes#jcite">578 F.3d 203</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1BGQ68003?jcsearch=578%20f%203d%20203&amp;summary=yes#jcite">211</a> (3d Cir.2009). With respect to 12(b)(1)
motions in particular, "[t]he plaintiff must assert facts that affirmatively
and plausibly suggest that the pleader has the right he claims (here, the
right to jurisdiction), rather than facts that are merely consistent with
such a right." <i>Stalky v. Catholic Health Initiatives</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X182KAU003?jcsearch=509%20f%203d%20517&amp;summary=yes#jcite">509 F.3d 517</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X182KAU003?jcsearch=509%20f%203d%20517&amp;summary=yes#jcite">521</a> (8th
Cir.2007).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>III.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Article III of the Constitution limits the scope of the Federal judicial
power to the adjudication of "cases" or "controversies." U.S. Const. art.
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/1?citation=USCONST%20Art.%20III&amp;summary=yes#jcite">III</a>, &sect; <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/1?citation=USCONST%20Art.%20III,%20%C2%A7%202&amp;summary=yes#jcite">2</a>. This "bedrock requirement," <i>Valley Forge Christian Coll. v. Ams.</i>
<i>United for Separation of Church &amp; State, Inc.</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CA6O?jcsearch=454%20us%20464&amp;summary=yes#jcite">454 U.S. 464</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CA6O?jcsearch=454%20us%20464&amp;summary=yes#jcite">471</a>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CA6O?jcsearch=102%20supreme%20court%20752&amp;summary=yes#jcite">102 S.Ct. 752</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CA6O?jcsearch=70%20l%20ed%202d%20700&amp;summary=yes#jcite">70 L.Ed.2d 700</a> (1982), protects the system of separated
powers and respect for the coequal branches by restricting the province of
the judiciary to "decid[ing] on the rights of individuals." <i>Marbury v.</i>
<i>Madison</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XJLPEN?jcsearch=5%20U.S.%20137&amp;summary=yes#jcite">5 U.S. (1 Cranch) 137</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/1?citation=5%20us%20137&amp;summary=yes#jcite">170</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XJLPEN?jcsearch=2%20l%20ed%2060&amp;summary=yes#jcite">2 L.Ed. 60</a> (1803). Indeed, "'[n]o
principle is more fundamental to the judiciary's proper role in our system
of government than the constitutional limitation of federal-court
jurisdiction to actual cases or controversies.'" <i>Raines v. Byrd</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CCV8?jcsearch=521%20us%20811&amp;summary=yes#jcite">521 U.S. 811</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CCV8?jcsearch=521%20us%20811&amp;summary=yes#jcite">818</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CCV8?jcsearch=117%20supreme%20court%202312&amp;summary=yes#jcite">117 S.Ct. 2312</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CCV8?jcsearch=138%20l%20ed%202d%20849&amp;summary=yes#jcite">138 L.Ed.2d 849</a> (1997) (quoting <i>Simon v.</i>
<i>E. Ky. Welfare Rights Org.</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C956?jcsearch=426%20us%2026&amp;summary=yes#jcite">426 U.S. 26</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C956?jcsearch=426%20us%2026&amp;summary=yes#jcite">37</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C956?jcsearch=96%20supreme%20court%201917&amp;summary=yes#jcite">96 S.Ct. 1917</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C956?jcsearch=48%20l%20ed%202d%20450&amp;summary=yes#jcite">48 L.Ed.2d 450</a>
(1976)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The courts have developed several justicability doctrines to enforce the
case-or-controversy requirement, and "perhaps the most important of these
doctrines" is the requirement that "a litigant have 'standing' to invoke the
power of a federal court." <i>Allen v. Wright</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CB0C?jcsearch=468%20us%20737&amp;summary=yes#jcite">468 U.S. 737</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CB0C?jcsearch=468%20us%20737&amp;summary=yes#jcite">750</a>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CB0C?jcsearch=104%20supreme%20court%203315&amp;summary=yes#jcite">104 S.Ct. 3315</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CB0C?jcsearch=82%20l%20ed%202d%20556&amp;summary=yes#jcite">82 L.Ed.2d 556</a> (1984). "[T]he standing question is whether
the plaintiff has 'alleged such a personal stake in the outcome of the
controversy' as to warrant his invocation of federal-court jurisdiction and
to justify exercise of the court's remedial powers on his behalf." <i>Warth</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C918?jcsearch=422%20us%20490&amp;summary=yes#jcite">422 U.S. at 498-99</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C918?jcsearch=95%20supreme%20court%202197&amp;summary=yes#jcite">95 S.Ct. 2197</a> (citing <i>Baker v. Carr</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C57E?jcsearch=369%20us%20186&amp;summary=yes#jcite">369 U.S. 186</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C57E?jcsearch=369%20us%20186&amp;summary=yes#jcite">204</a>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C57E?jcsearch=82%20supreme%20court%20691&amp;summary=yes#jcite">82 S.Ct. 691</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C57E?jcsearch=7%20l%20ed%202d%20663&amp;summary=yes#jcite">7 L.Ed.2d 663</a> (1962)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The plaintiff bears the burden of meeting the "irreducible constitutional
minimum" of Article III standing by establishing three elements:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      First, the plaintiff must have suffered an injury in fact &mdash; an
    invasion of a legally protected interest which is (a) concrete and
    particularized and (b) actual or imminent, not conjectural or
    hypothetical. Second, there must be a causal connection between the
    injury and the conduct complained of &mdash; the injury has to be fairly
    traceable to the challenged action of the defendant, and not the
    result of the independent action of some third party not before the
    court. Third, it must be likely, as opposed to merely speculative,
    that the injury will be redressed by a favorable decision.
<span CLASS="page_no" data-cite="2012 bl 121265 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[**8]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Lujan v. Defenders of Wildlife</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CC5D?jcsearch=504%20us%20555&amp;summary=yes#jcite">504 U.S. 555</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CC5D?jcsearch=504%20us%20555&amp;summary=yes#jcite">560-61</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CC5D?jcsearch=112%20supreme%20court%202130&amp;summary=yes#jcite">112 S.Ct. 2130</a>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CC5D?jcsearch=119%20l%20ed%202d%20351&amp;summary=yes#jcite">119 L.Ed.2d 351</a> (1992) (internal quotations, alterations, and citations
omitted).
<span CLASS="page_no" data-cite="678 f 3d 245" data-cite-type="PrimaryFederalReporter" data-cite-pageno="245" data-primary-citation="678 F.3d 235">[*245]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We have recognized that of the three required elements of constitutional
standing, "the injury-in-fact element is often determinative." <i>Toll Bros.,</i>
<i>Inc. v. Turp. of Readmgton</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1AGVK2003?jcsearch=555%20f%203d%20131&amp;summary=yes#jcite">555 F.3d 131</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1AGVK2003?jcsearch=555%20f%203d%20131&amp;summary=yes#jcite">138</a> (3d Cir.2009). To satisfy this
requirement, the alleged injury must be "particularized," in that it "must
affect the plaintiff in a personal and individual way." <i>Lujan</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CC5D?jcsearch=504%20us%20555&amp;summary=yes#jcite">504 U.S. at 560</a> n. 1, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CC5D?jcsearch=112%20supreme%20court%202130&amp;summary=yes#jcite">112 S.Ct. 2130</a>. "[T]he 'injury in fact' test requires
more than an injury to a cognizable interest. It requires that the party
seeking review be himself among the injured." <i></i><a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CC5D?jcsearch=504%20U.S.%20at%20560&amp;summary=yes#jcite">Id. at 563</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CC5D?jcsearch=112%20supreme%20court%202130&amp;summary=yes#jcite">112 S.Ct. 2130</a>
(quoting <i>Sierra Club v. Morton</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C879?jcsearch=405%20us%20727&amp;summary=yes#jcite">405 U.S. 727</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C879?jcsearch=405%20us%20727&amp;summary=yes#jcite">734-35</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C879?jcsearch=92%20supreme%20court%201361&amp;summary=yes#jcite">92 S.Ct. 1361</a>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5C879?jcsearch=31%20l%20ed%202d%20636&amp;summary=yes#jcite">31 L.Ed.2d 636</a> (1972)). The injury must also be "an invasion of a legally
protected interest." <i></i><a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CC5D?jcsearch=504%20U.S.%20at%20560&amp;summary=yes#jcite">Id. at 560</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CC5D?jcsearch=112%20supreme%20court%202130&amp;summary=yes#jcite">112 S.Ct. 2130</a>. Since "standing is not
dispensed in gross," <i>Lewis v. Casey</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CCS1?jcsearch=518%20us%20343&amp;summary=yes#jcite">518 U.S. 343</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CCS1?jcsearch=518%20us%20343&amp;summary=yes#jcite">358</a> n. 6, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CCS1?jcsearch=116%20supreme%20court%202174&amp;summary=yes#jcite">116 S.Ct. 2174</a>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CCS1?jcsearch=135%20l%20ed%202d%20606&amp;summary=yes#jcite">135 L.Ed.2d 606</a> (1996), a plaintiff who raises multiple causes of action
"must demonstrate standing for each claim he seeks to press."
<i>DaimlerChrysler Corp. v. Cuno</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X151TOA003?jcsearch=547%20us%20332&amp;summary=yes#jcite">547 U.S. 332</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X151TOA003?jcsearch=547%20us%20332&amp;summary=yes#jcite">352</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X151TOA003?jcsearch=126%20supreme%20court%201854&amp;summary=yes#jcite">126 S.Ct. 1854</a>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X151TOA003?jcsearch=164%20l%20ed%202d%20589&amp;summary=yes#jcite">164 L.Ed.2d 589</a> (2006). Furthermore, "the standing inquiry requires careful
judicial examination of a complaint's allegations to ascertain whether the
particular plaintiff is entitled to an adjudication of the particular claims
asserted." <i>Allen</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CB0C?jcsearch=468%20us%20737&amp;summary=yes#jcite">468 U.S. at 752</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CB0C?jcsearch=104%20supreme%20court%203315&amp;summary=yes#jcite">104 S.Ct. 3315</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>A. Local 331</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The District Court dismissed the TPP Complaint in its entirety for lack of
standing and failure to state a claim. Local 331 contends that the Court
applied the wrong standard of review and consequently erred in finding that
the TPP Complaint fails to adequately plead facts to establish an
injury-in-fact that is fairly traceable to the Defendants' alleged
misconduct. Local 331 also argues that the Court erred in finding that it
failed to state a claim for tortious interference with contract and un-just
enrichment. We address each of these arguments in turn.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Counts I and II of the TPP Complaint assert causes of action under the
federal and New Jersey RICO statutes, respectively. The federal RICO statute
creates a civil remedy, including an award of treble damages, costs, and
attorneys fees, for "any person injured in his business or property" by a
violation of one of RICO's substantive provisions. <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEHSSA003?jcsearch=18%20U.S.C.%20%201964(c)&amp;summary=yes#jcite">18 U.S.C. &sect; 1964</a>(c).
Pursuant to <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEHSS6003?jcsearch=18%20U.S.C.%20%201962(c)&amp;summary=yes#jcite">18 U.S.C. &sect; 1962</a>(c), it is unlawful for "'any person' who is
employed by or associated with 'any enterprise' affecting interstate
commerce to 'participate, directly or indirectly, in the conduct of such
enterprise's affairs through a pattern of racketeering activity.'" <i>Genty v.</i>
<i>Resolution Trust Corp.</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XAC74C?jcsearch=937%20f%202d%20899&amp;summary=yes#jcite">937 F.2d 899</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XAC74C?jcsearch=937%20f%202d%20899&amp;summary=yes#jcite">906</a> (3d Cir.1991) (quoting
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEHSS6003?jcsearch=18%20U.S.C.%20%201962(c)&amp;summary=yes#jcite">18 U.S.C. &sect; 1962</a>(c)). The RICO statute defines racketeering activity by a
list of crimes, or "predicate offenses," including several state felonies
such as murder, kidnapping, and bribery that are punishable by imprisonment
for more than one year, and federal crimes such as bribery, mail fraud and
wire fraud. <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEHSS4003?jcsearch=18%20U.S.C.%20%201961(1)&amp;summary=yes#jcite">18 U.S.C. &sect; 1961</a>(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The TPP Complaint also alleges violations of the New Jersey RICO statute,
N.J. Stat. Ann. &sect; <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XCMSKK003?jcsearch=N.J.%20Stat.%20Ann.%20%202C:41-4(c)&amp;summary=yes#jcite">2C:41-4</a>(c), based on the same alleged enterprises,
predicate offenses, and pattern of racketeering activity as those alleged in
support of the federal RICO claims. (TPP Compl. &para; 396-103.) Since the TPP
Complaint's federal and New Jersey RICO claims parallel each other, and
because the two RICO statutes are intended to be coextensive, <span CLASS="page_no" data-cite="2012 bl 121265 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[**9]</span> we follow the
District Court's approach and analyze the two claims concurrently. (<i>See A.</i>
86, n.3); <i>see also Cetel v. Kirwan Fin. Grp., Inc.</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X15JEJG003?jcsearch=460%20f%203d%20494&amp;summary=yes#jcite">460 F.3d 494</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X15JEJG003?jcsearch=460%20f%203d%20494&amp;summary=yes#jcite">510</a> (3d
Cir.2006) ("[T]he New Jersey Supreme Court believed the New Jersey RICO
statute was and should be consistent with the federal
<span CLASS="page_no" data-cite="678 f 3d 246" data-cite-type="PrimaryFederalReporter" data-cite-pageno="246" data-primary-citation="678 F.3d 235">[*246]</span> 
RICO statute.") (citing <i>State v. Ball</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X2VHQM?jcsearch=141%20new%20jersey%20142&amp;summary=yes#jcite">141 N.J. 142</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X2VHQM?jcsearch=661%20atlantic%202d%20251&amp;summary=yes#jcite">661 A.2d 251</a> (1995)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In addition to meeting the constitutional standing requirements,
"plaintiffs seeking recovery under RICO must satisfy additional standing
criterion set forth in <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEHSSA003?jcsearch=18%20U.S.C.%20%201964(c)&amp;summary=yes#jcite">section 1964(c)</a> of the statute." <i>Maio v. Aetna, Inc.</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X3ITMA?jcsearch=221%20f%203d%20472&amp;summary=yes#jcite">221 F.3d 472</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X3ITMA?jcsearch=221%20f%203d%20472&amp;summary=yes#jcite">482</a> (3d Cir.2000). <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEHSSA003?jcsearch=18%20U.S.C.%20%201964(c)&amp;summary=yes#jcite">Section 1964(c)</a> confers standing upon "any
person injured in his business or property by reason of a violation of
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEHSS6003?jcsearch=18%20U.S.C.%20%201962&amp;summary=yes#jcite">section 1962</a> of this chapter . . ." <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEHSSA003?jcsearch=18%20U.S.C.%20%201964(c)&amp;summary=yes#jcite">18 U.S.C. &sect; 1964</a>(c). We have interpreted
this language as requiring RICO plaintiffs to "make two related but
analytically distinct threshold showings" to establish standing: "(1) that
the plaintiff suffered an injury to business or property; and (2) that the
plaintiffs injury was proximately caused by the defendant's violation of
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/XEHSS6003?jcsearch=18%20usc%201962&amp;summary=yes#jcite">18 U.S.C. &sect; 1962</a>." <i>Maio</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X3ITMA?jcsearch=221%20f%203d%20472&amp;summary=yes#jcite">221 F.3d at 483</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The District Court in this case conducted an extensive analysis of the TPP
Complaint to determine if it complied with the RICO standing requirement of
alleging injury to business or property. It concluded that the TPP Complaint
did not allege a concrete injury to TPP business or property because it did
not contain sufficient allegations that they paid for prescriptions of the
drugs that were actually ineffective or otherwise worth less than what they
paid for them. On appeal, the parties focused their arguments, in
significant part, on debating this conclusion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although we agree with the District Court's conclusion in this respect, we
need not reach the question of standing under RICO. It is well-established
that a plaintiffs Article III standing is a prerequisite for the federal
courts to decide the merits of a suit. <i>See Steel Co. v. Citizens for a</i>
<i>Better Environment</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CD0R?jcsearch=523%20us%2083&amp;summary=yes#jcite">523 U.S. 83</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CD0R?jcsearch=523%20us%2083&amp;summary=yes#jcite">109-10</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CD0R?jcsearch=118%20supreme%20court%201003&amp;summary=yes#jcite">118 S.Ct. 1003</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CD0R?jcsearch=140%20l%20ed%202d%20210&amp;summary=yes#jcite">140 L.Ed.2d 210</a>
(1998). Therefore, prior to considering whether Local 331 has standing to
bring a RICO claim, we must determine whether it has Article III standing to
invoke the jurisdiction of this Court. Because we find that Local 331 has
not established that its alleged injury is fairly traceable to Schering's
alleged wrongful conduct, we conclude that the Complaint was properly
dismissed for lack of Article III standing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The District Court held that the TPP Complaint fails to sufficiently
allege facts to establish that the plaintiffs' off-label purchases of the
Subject Drugs &mdash; "assuming one were to constitute injury-in-fact" &mdash; is fairly
traceable to Schering's allegedly unlawful marketing practices, and
"specifically to misrepresentations about the [drugs] and/or to conduct
characterized as bribery." (A. 95.) On appeal, Local 331 argues that if the
Court had "properly applied [the causation] standard to the plausibility
test, it would have determined that there is a traceable connection from
Local 331's injuries to the Defendant's illegal marketing scheme." (Local
331 Br. at 18.)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We limit our analysis to the injury and causation theories that Local 331
raises on appeal.<a HREF="#fn300" name="fnref_fn300">[fn3]</a> In the Statement of Case section of <span CLASS="page_no" data-cite="2012 bl 121265 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[**10]</span> its Brief, Local
331 mentions three distinct injuries. First, it paid for off label
prescriptions that were ineffective. Second, it paid for off label
prescriptions when less expensive but equally effective medication was
available. And third, it "paid for elevated drug prices that recouped the
costs of Schering's illegal marketing." (Local <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/1?citation=331%20Br.%20At%204&amp;summary=yes#jcite">331 Br. At 4</a>.) The argument
section of its Brief, however, is limited to economic loss based on paying
<span CLASS="page_no" data-cite="678 f 3d 247" data-cite-type="PrimaryFederalReporter" data-cite-pageno="247" data-primary-citation="678 F.3d 235">[*247]</span> 
for ineffective drugs. Accordingly, we further limit our analysis to the
question of whether the TPP complaint alleges a causal link between the
challenged conduct and the injury that Local 331 actually argues on appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, Local 331 defends its standing to sue in large part on the
basis of drug purchases made by the other TPP Plaintiffs. It cites
allegations that the Defendants made false claims about Temodar and
Intron-A, and the other TPP Plaintiffs' purchases of those drugs for
off-label indications. (Local <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/1?citation=331%20bankruptcy%2014&amp;summary=yes#jcite">331 B.R. at 14-17</a>.) Such allegations are
unhelpful to Local 331, which does not allege that it ever paid for a
Temodar or Intron-A prescription. <i>See Lewis v. Casey</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CCS1?jcsearch=518%20us%20343&amp;summary=yes#jcite">518 U.S. 343</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CCS1?jcsearch=518%20us%20343&amp;summary=yes#jcite">347</a>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CCS1?jcsearch=116%20supreme%20court%202174&amp;summary=yes#jcite">116 S.Ct. 2174</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CCS1?jcsearch=135%20l%20ed%202d%20606&amp;summary=yes#jcite">135 L.Ed.2d 606</a> (1996) (requiring named plaintiffs in a
putative class action to allege "that they personally have been injured, not
that injury has been suffered by other, unidentified members of the class. .
. ."). Accordingly, we will assess whether the TPP Complaint contains
sufficient factual allegations to confer standing upon Local 331 based upon
its alleged purchases.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  According to the TPP Complaint, Local 331's damages are limited to two
prescriptions of Rebetol:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Member Kraft and Member Maurone were both prescribed Rebetol
    during the Class Period which were paid for in large part by Local
    331. Upon information and belief, these prescriptions were written
    for off-label uses by physicians improperly influenced by the false
    and misleading statements, bribes, and other dishonest inducements
    brought to bear by Defendants' illegal off-label marketing scheme.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
(TPP Compl. &para; 21.)<a HREF="#fn400" name="fnref_fn400">[fn4]</a> Accordingly, to establish standing, Local 331 must
allege facts showing a causal relationship between the alleged injury &mdash;
payments for Rebetol that was ineffective or unsafe for the use for which it
was prescribed &mdash; and Schering's alleged wrongful conduct.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To show the requisite causal connection, Local 331 must allege sufficient
facts to plausibly support "a causal connection between the injury and the
conduct complained of &mdash; the injury has to be fairly traceable to the
challenged action of the defendant, and not the result of the independent
action of some third party not before the court." <i>Lujan</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CC5D?jcsearch=504%20us%20555&amp;summary=yes#jcite">504 U.S. at 560</a>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CC5D?jcsearch=112%20supreme%20court%202130&amp;summary=yes#jcite">112 S.Ct. 2130</a>. In other words, the Amended Complaint must allege facts that
plausibly support a causal connection between Local 331's injury-in-fact and
Schering's allegedly illegal marketing or bribery schemes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In arguing that the TPP Complaint meets this burden, Local 331 essentially
repeats the reasoning that the District Court rejected. Specifically, it
states that the TPP Complaint alleges both "an overwhelming and
reprehensible pattern of deceit by the defendants," including <span CLASS="page_no" data-cite="2012 bl 121265 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[**11]</span> false
marketing and illegal inducements to doctors, and that this scheme was aimed
at the TPPs. (Local <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/1?citation=331%20bankruptcy%2018&amp;summary=yes#jcite">331 B.R. at 18-19</a>.) Local 331 refers to allegations that
Schering "falsely marketed the Intron Franchise Drugs as efficacious" for
off-label uses, but cites only to paragraphs that discuss Intron-A. (<i>See</i> TPP
Compl. &para; 178, 181, 182.) Likewise, Local 331 argues that Schering paid
doctors to prescribe the
<span CLASS="page_no" data-cite="678 f 3d 248" data-cite-type="PrimaryFederalReporter" data-cite-pageno="248" data-primary-citation="678 F.3d 235">[*248]</span> 
drugs to patients who did not need them, but cites only to paragraphs
referring to Intron-A, Temodar, or Rebetron. (See TPP Compl. &para; 15-16, 18,
36, 317-60, 278-89); (Local <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/1?citation=331%20bankruptcy%2019&amp;summary=yes#jcite">331 B.R. at 19</a>). Local 331 apparently believes
that these allegations are an adequate basis to conclude that, but-for
Schering's illegal conduct that increased off-sale prescriptions, "Local 331
either would not have had to pay for them, or would not have had to pay for
them at increased prices over readily-available therapies." (<i></i><cite>Id. at 19</cite>.)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Local 331's suggestion that the claims about the other drugs are what
caused the doctors to prescribe Rebetol for off-label uses is inadequate to
establish causation. Local 331 claims that the allegations about the other
Subject Drugs, paired with the fact that "Schering alone marketed Rebetol,"
together reasonably support the inference that "discovery will almost
certainly confirm" that Schering also made "false statements about all the
drugs described in the Complaint." (Local 331 Reply at 11.) Local 331 must
allege facts sufficient to show that the Rebetol which it paid for was
prescribed to its members for ineffective off-label uses <i>because of</i>
Schering's alleged misconduct. There are no averments that come close to
satisfying this standard. It is pure conjecture to conclude that because
Schering's misconduct caused other doctors to write prescriptions for
ineffective off-label uses for other products, Local 331 ended up paying for
two prescriptions for Rebetol due to the same kind of misconduct.
Accordingly, Local 331 has failed to show the requisite causal relationship
between the alleged misconduct and its alleged injury. Therefore, dismissal
for lack of standing is warranted.<a HREF="#fn500" name="fnref_fn500">[fn5]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>B. Montgomery</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Montgomery, a consumer of Rebetol and PEG-Intron, brought the MAC on
behalf of a putative nationwide class of consumers of the Subject Drugs. The
MAC alleges facts particular to her experience and use of two of the Subject
Drugs, as well as the various legal theories pursued on behalf of the
consumer plaintiffs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Montgomery suffered from Hepatitis C, a viral liver infection, and after
tests conducted in 1999 showed that she was asymptomatic, her physician, Dr.
Jeffrey R. Willis, decided not to prescribe her a combination therapy of
Rebetol and Intron-A. At a follow-up visit in September 2001, Dr. Willis
recommended a different treatment plan,<a HREF="#fn600" name="fnref_fn600">[fn6]</a> even though Montgomery was
still asymptomatic. A few months after this consultation, Dr. Willis
prescribed
<span CLASS="page_no" data-cite="678 f 3d 249" data-cite-type="PrimaryFederalReporter" data-cite-pageno="249" data-primary-citation="678 F.3d 235">[*249]</span> 
Montgomery the PEG-Intron and Rebetol combination therapy, also called the
"PEG-Intron Combination Therapy." (MAC &para; 75.)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The MAC avers that at the time she was prescribed the Subject Drugs, they
were only approved for patients with compensated <span CLASS="page_no" data-cite="2012 bl 121265 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[**12]</span> liver disease, and that
since she was healthy and did not need treatment, she suffered from the
serious side effects of the drugs and lost weeks of work due to these side
effects. The MAC further claims that Dr. Willis changed his mind about her
treatment plan because of Schering's improper marketing of the
Rebetol/PEG-Intron combination therapy. Specifically, it alleges: "Dr.
Willis' new plan for Mrs. Montgomery's treatment for her asymptomatic
Hepatitis C evidences that he was subjected to the marketing and sales
scheme by Schering alleged in this Amended Complaint." (MAC 130.)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The MAC reaches this conclusion based on the alleged facts that: (1) due
to Schering's off-label marketing techniques, Dr. Willis mistakenly believed
that the combination therapy was the standard treatment for Montgomery's
condition; (2) Dr. Willis prescribed the combination therapy before sending
Montgomery for two tests that he suggested were necessary before beginning
the treatment; (3) Dr. Willis received misinformation from a nurse on his
staff who was believed to be a Schering-paid nurse.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The MAC contains extensive factual allegations regarding the types of
improper marketing techniques that Schering used, which Montgomery alleges
must have influenced Dr. Willis between 1999, when he declined to prescribe
her the drugs, and 2001, when he changed his treatment plan. The MAC
reasserts many of the same allegations about Schering's techniques alleged
in the TPP Complaint. The MAC also incorporates by reference all of the
factual allegations made in a Qui Tarn action brought against Schering in
the District of Massachusetts, and the allegations in the Criminal
Information, discussed above, to which Schering pleaded guilty. (MAC &para;
99-101.) The allegations include claims about Schering's scheme for
providing kickbacks to doctors for prescribing the drugs, false promotional
claims made by sales representatives, and the placement of a Schering-paid
nurse on Dr. Willis' staff. The MAC further alleges that Montgomery "would
not have been prescribed and would not have paid for such a costly, noxious,
and dangerous medication cocktail had she known all the facts that were
concealed by Defendants and her doctors. . . ." (MAC &para; 4, 5.)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Defendants moved to dismiss the MAC under <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(1)&amp;summary=yes#jcite">Rule 12(b)(1)</a>. The District
Court dismissed the MAC for lack of jurisdiction under <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(1)&amp;summary=yes#jcite">Rule 12(b)(1)</a>,
finding that it failed to establish a sufficient nexus between her alleged
injury and Schering's alleged misconduct.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In reaching this conclusion, the Court first found that Montgomery had
alleged an adequate injury-in-fact for her claims under the Washington
Consumer Protection Act and various common law theories. The District Court
held, however, that her "standing to bring suit founders on her inability to
establish any nexus between her purported injury &mdash; be it the needless
purchase of the Rebetol/PEG-Intron, the side-effects she claims to have
suffered and/or the lost work time &mdash; and the wrongful conduct in which
Schering was allegedly engaged." (A. 117.) Montgomery's theory that the
Defendants <span CLASS="page_no" data-cite="2012 bl 121265 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[**13]</span> injured her is premised on whether Dr. Willis shifted his opinion
about the appropriate treatment plan due to Schering's marketing practices.
The District Court found that the MAC "fails to provide any factual
allegations
<span CLASS="page_no" data-cite="678 f 3d 250" data-cite-type="PrimaryFederalReporter" data-cite-pageno="250" data-primary-citation="678 F.3d 235">[*250]</span> 
that would support [this] conclusion." (A. 118.)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, Montgomery challenges the Court's dismissal of the MAC on
several grounds. She argues that the Court improperly failed to consider
certain factual allegations, some of which she claims establish the
necessary causal link. Moreover, with respect to the factual allegations
that the Court did consider, Montgomery argues that it applied an improper
standard in rejecting those allegations as inadequate, and claims that when
reviewed under the proper standard, they do adequately allege a causal
nexus.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Montgomery first challenges the District Court's decision on the ground
that it erred in not fully considering "the entirety of the record" and
taking all factual allegations as true. Montgomery notes that the MAC
"incorporates several other documents that set forth in great detail &mdash;
beyond the extraordinary detail contained in the complaint itself &mdash; the
nature and extent of Schering's alleged unfair deceptive acts and
practices." (Montgomery Br. at 25.) These documents include: (1) factual
averments based on the personal knowledge of three former Schering employees
in their related qui tarn case filed in the District of Massachusetts
(incorporated in the MAC at &para; 105); (2) factual allegations about the
Subject Drugs detailed in the related TPP Amended Complaint (incorporated in
the MAC at n. 1, A. 987); (3) the Criminal Information to which Schering
pleaded guilty (incorporated in the MAC at &para; 101); (4) the factual averments
in the Settlement Agreement in the criminal case (incorporated in the MAC at
&para; 102); and (5) the Corporate Integrity Agreement and addendum to the same
in the criminal case (incorporated in the MAC at &para; 103). (Montgomery Br. at
25-26.) Montgomery asserts that "it is not clear from the district court's
opinion that it took proper account of these documents, and the substantial
facts contained therein, in its ruling." (<i></i><cite>Id. at 26</cite>.)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In regard to these documents, the District Court stated:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Plaintiff apparently believes that somehow, through the
    incorporation of allegations made in other proceedings, such as the
    False Claims Act action filed by three qui tarn relators, she can
    pursue her own relief against Schering. The irreducible minimum of
    Article III standing, however, requires Montgomery to demonstrate
    that she, personally, has suffered a concrete injury, that her
    injury can be traced to Schering's misconduct and that it is capable
    of redress by the Court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
(A. 120.) This statement suggests that the District Court did not permit
Montgomery to rely on factual allegations that pertain to the standing of
other parties in order to establish her own standing. The Court also stated
that it did not ignore those documents: "Assuming Schering engaged in all of
the marketing practices detailed in [the MAC] and in documents incorporated
by reference, and assuming <span CLASS="page_no" data-cite="2012 bl 121265 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[**14]</span> that the practices might be deemed unlawful, none
of the factual allegations she makes establish the required nexus between
her injury and Schering's actions." (A. 120-21.)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is thus clear that the District Court did not ignore the documents that
Montgomery sought to incorporate by reference in her Amended Complaint. It
is also clear that the District Court properly concluded that the averments
of misconduct did not support a non-conjectural conclusion that Dr. Willis
had been induced by such misconduct to order the PEG-Intron Combination
Therapy. Moreover, as a general matter, even if the Court did decline to
consider some of these documents, this was not necessarily an error. Under
Fed.R.Civ.P. <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X144L0U003?jcsearch=Fed.%20R.%20Civ.%20P.%208(a)(2)&amp;summary=yes#jcite">8</a>(a)(2), a complaint should
<span CLASS="page_no" data-cite="678 f 3d 251" data-cite-type="PrimaryFederalReporter" data-cite-pageno="251" data-primary-citation="678 F.3d 235">[*251]</span> 
set forth a "short and plain statement" of the claim to relief. Plaintiffs
cannot be permitted to incorporate an endless series of external documents
into a complaint simply "by reference" to them, as this would lead to an
impossible task for defendants in filing their answers, and for courts in
reviewing the sufficiency of complaints. In any event, to the extent that
Montgomery specifically claims that this alleged failure to consider
particular allegations in the incorporated documents has prejudiced her &mdash;
that is, that such allegations would have cured any of the deficiencies in
stating causation &mdash; we discuss those arguments <i>infra.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To establish standing, the MAC sought to allege a causal nexus between Dr.
Willis' decision to prescribe the drugs to Montgomery, and the Defendants'
alleged fraudulent marketing and bribery schemes. The District Court held
that the MAC failed to adequately allege any connection between Schering's
alleged bribery scheme and Montgomery's experience. The Court explained that
the MAC "lacks any allegation either directly accusing or even plausibly
suggesting that . . . Dr. Willis received [illegal] remunerations." (A.
120.) The Court also rejected the MAC's allegation about Dr. Willis's
involvement in a clinical trial:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      In the case of Mrs. Montgomery and other asymptomatic Hepatitis C
    patients at [Dr. Willis' practice], upon information and belief
    based upon the evidence of record, it is alleged that Defendants
    engaged Dr. Willis in a phony clinical trial respecting Rebetron
    Combination Therapy beginning shortly after the August 2001 FDA
    approval letter issued.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
(MAC &para; 93.)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Court found this allegation inadequate because it was "conclusory."
(A. 120.) Even "assum[ing] the truth of fact asserted," and "credit[ing] the
allegation that Dr. Willis was involved in a clinical trial," the Court
refused to "credit the bald assertion that the trial was 'phony,' presumably
meaning that Dr. Willis was not actually gathering data and studying
patients . . . but [was only a] subterfuge for collecting payments from
Schering for prescribing the drugs being studied." (A. 120.) It rejected
this assertion because "[n]othing in the [MAC] supports this
characterization." (A. 120.)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, Montgomery argues that the Court wrongly refused to accept this
allegation as true. In our view, even if we found these arguments to be
meritorious, <span CLASS="page_no" data-cite="2012 bl 121265 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[**15]</span> they are still unavailing. Even if we accepted the MAC's
allegation that Dr. Willis was involved in a "phony" clinical trial for
Rebetron Combination Therapy, this fact does not establish the necessary
causal connection between Schering's misconduct and Montgomery's injury,
because she was not prescribed the Rebetron Combination Therapy. To the
contrary, she was prescribed the PEG-Intron Combination Therapy, a
combination of Rebetol and another longer-lasting form of interferon,
PEG-Intron. (See MAC &para; 23, 64-66, 74.)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Thus, as Schering observes: "Dr. Willis's thoughts or clinical experiences
with that drug therapy are of no moment here." (Schering Br. at 26.)
Notably, Montgomery does not apparently challenge this contention in her
Reply Brief. In our view, the fact that the allegedly "phony" trial did not
even concern a treatment regimen that her doctor prescribed to her is
dispositive. There is no allegation of fact that supports a connection
between Schering's unlawful conduct of involving Dr. Willis in a "phony"
trial, and Montgomery's prescription for a different drug therapy.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Montgomery's other arguments are equally unpersuasive. She contends that
the Court "unfairly rebuke[d] [her] for not
<span CLASS="page_no" data-cite="678 f 3d 252" data-cite-type="PrimaryFederalReporter" data-cite-pageno="252" data-primary-citation="678 F.3d 235">[*252]</span> 
'directly accusing her doctor of a crime &mdash; i.e., engaging in a phony
clinical trial &mdash; and defrauding his patients and the government."
(Montgomery Br. at 27.) She also invokes <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X144L14003?jcsearch=Fed.%20R.%20Civ.%20P.%2011&amp;summary=yes#jcite">Rule 11</a> to argue that her lawyers
were not permitted to make such an allegation about Dr. Willis at this time.
(<i></i><cite>Id. at 28</cite>.) She continues: "[t]he fundamental problem with the district
court's dismissal is that the court required some direct accusation of
criminal conduct by a non-party at the pleading stage. It was wrong to do
so." (<i><cite>Id</cite>.</i>)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This argument misconstrues the District Court's analysis, which did not
require the MAC to charge Dr. Willis with a crime. Rather, the Court
considered the allegation that the trial was "phony" to be conclusory
because there was simply no other allegation in the MAC to support the
assertion that this particular trial was in fact a disguised bribery scheme.
To satisfy the standard, the MAC would not have to allege that Dr. Willis
had committed a crime, but state factual allegations suggesting that the
clinical trial was in fact somehow fraudulent or undertaken in bad faith.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Montgomery argues that the MAC contains allegations that support the claim
that the trial was "phony," including an allegation citing to a memorandum
from one of the qui tarn relators, a Schering employee who stated that "his
job is secure" in part because he had "over 50 [Hepatitis] trials underway."
(Montgomery Br. at 30, citing MAC &para; 94-95.) This general assertion that 50
Hepatitis clinical trials were underway, however, does not support the
conclusion that Dr. Willis's trial was one of those phony trials. These
allegations therefore do not "bolster the main allegation" that Dr. Willis
was involved in a "phony" clinical trial. (<i></i><cite>Id. at 30</cite>.)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Montgomery points to no other factual allegations in the MAC that support
the conclusion that Dr. Willis was in any way connected with phony trials.
The allegation therefore <span CLASS="page_no" data-cite="2012 bl 121265 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[**16]</span> does appear to be a speculative conclusion that
falls short of stating facts that raise a "plausible" right to relief. We
conclude that the Court did not err in rejecting the assertion, without
other supporting factual claims, that Dr. Willis was involved in a phony
clinical trial. <i>See Morse v. Lower Merion Sch. Dist.</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X4Q4CU?jcsearch=132%20f%203d%20902&amp;summary=yes#jcite">132 F.3d 902</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X4Q4CU?jcsearch=132%20f%203d%20902&amp;summary=yes#jcite">906</a> (3d
Cir.1997) (holding that a court reviewing a complaint need not credit "bald
assertions" or "legal conclusions").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The MAC also claimed that three other Schering-sponsored programs
associated with Montgomery's treatment under Dr. Willis were the causal link
between his prescription and Schering's false marketing campaign. First, the
MAC alleges that a Schering-paid nurse in Dr. Willis' office, identified in
the MAC as "D.S." or "Diana S.," was part of the marketing scheme that
affected her treatment. (MAC &para; 42-25.) The Court held that this allegation
that Diana S. "was part of Schering's deceitful marketing scheme and somehow
caused Dr. Willis to prescribe Rebetol/PEG-Intron to Montgomery is purely
conclusory." (A. 119.) The Court reasoned that, at most, it could accept as
true the alleged facts, which stated that this nurse was paid by Schering to
provide patient support in matters concerning injection-training and side
effects; however, the Court concluded, "there is no indication that Schering
executed the alleged misrepresentations or kickbacks through this PCC." (A.
119.)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The MAC makes numerous allegations about "Diana S." based on "information
and belief; it never explains, however, the basis for its conclusion that
she was in fact employed by Schering, or that she disseminated any false
information to Dr. Willis
<span CLASS="page_no" data-cite="678 f 3d 253" data-cite-type="PrimaryFederalReporter" data-cite-pageno="253" data-primary-citation="678 F.3d 235">[*253]</span> 
about the Subject Drugs. In our view, the MAC fails to allege sufficient
facts to "show" that her treatment plan was influenced by Diana S. at the
behest of Schering.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The District Court also discredited the MAC's allegations with respect to
two other Schering-sponsored programs, the "Access Assurance Program" and
"Be in Charge Program." According to the MAC, the "Access Assurance Program"
supported patients who were undergoing treatments by the Subject Drugs by
ensuring they had a consistent supply of the product, and also allegedly to
serve as a marketing technique. (MAC &para; 48-51.) Similarly, the "Be in Charge"
program was designed to help support patients on Rebetron therapy by
providing them with a nurse to ensure "such patients were 'compliant'" with
the therapy program, so that Schering could "ensure that [it] sold as much
Rebetron Combination Therapy as possible." (MAC &para; 52.) However, the MAC
provides no factual allegations describing how either of these programs
interfered with Dr. Willis' decision to prescribe Montgomery the Subject
Drugs through any false information, or that it gave her any false claims
about the drugs that otherwise injured her. Accordingly, we conclude that
these allegations are not sufficient to form the necessary causal nexus.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Montgomery also raises a handful of other claims that are ultimately
unavailing. She argues that the MAC properly pleaded causes of action for
statutory consumer fraud, common <span CLASS="page_no" data-cite="2012 bl 121265 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[**17]</span> law conspiracy, aiding and abetting and
unjust enrichment. (Montgomery Br. at 45.) Montgomery argues that the Court
should have evaluated her standing to bring the claims with regard to each
particular claim, and notes that other than a brief discussion of the
Washington Consumer Protection Act, the Court's opinion contains "no
discussion of the elements of the plaintiffs four claims, or the sufficiency
of her allegations of the same in the MAC." (<i></i><cite>Id. at 46</cite>.) She requests that
we vacate the decision and remand it "for failure to adequately address the
first step of the requisite two-step process under <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012&amp;summary=yes#jcite">Rule 12</a>." (<i><cite>Id</cite>.</i>, quoting
<i>Fowler</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1BGQ68003?jcsearch=578%20f%203d%20203&amp;summary=yes#jcite">578 F.3d at 210</a> ("First, the factual and legal elements of a claim
should be separated.")). Montgomery then proceeds to exhaustively discuss
how the MAC pleads all of the requisite elements of each of her claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Montgomery's focus on the pleading standards for each of her claims is
secondary to the threshold issue that the Court addressed when determining
that the MAC did not adequately allege an injury fairly traceable to
Schering's alleged misconduct. Although the MAC is replete with factual
allegations and indeed asserts them with greater specificity than the TPP
Complaint, they do not present a plausible allegation actually linking
Montgomery's injuries to any type of miscommunication or false claim about
the drugs that were actually prescribed to her. Accordingly, we will affirm
the Court's conclusion that the MAC failed to adequately allege causation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>IV.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Neither appellant &mdash; Local 331 nor Montgomery &mdash; has alleged facts
sufficient to confer standing to seek relief for Schering's marketing of
certain drugs for off-label uses. Accordingly, we will affirm the District
Court's rulings.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> There are four TPPs named as plaintiffs: the International Brotherhood
of Teamsters Local No. 331 Health &amp; Welfare Fund ("Local 331"), Heavy and
General Laborers' Local Union 472/172 Welfare Fund, United American
Insurance Company, and Blue Cross Blue Shield of Alabama. Local 331 is the
only third-party payor to appeal. We are thus concerned only with the
standing of Local 331.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> This action originally included five named patients: Angela F.
Montgomery, Harold Estelle, Beryl A'Dare Brarton, Dorothy Brarton, and John
Huston. Only Angela F. Montgomery has continued to pursue this matter. We
are thus concerned only with Montgomery's standing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> We, of course, have no jurisdiction to decide the standing of those
TPP Plaintiffs who have not appealed. <i>See Torres v. Oakland Scavenger Co.</i>,
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CBL0?jcsearch=487%20us%20312&amp;summary=yes#jcite">487 U.S. 312</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CBL0?jcsearch=487%20us%20312&amp;summary=yes#jcite">317</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CBL0?jcsearch=108%20supreme%20court%202405&amp;summary=yes#jcite">108 S.Ct. 2405</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X5CBL0?jcsearch=101%20l%20ed%202d%20285&amp;summary=yes#jcite">101 L.Ed.2d 285</a> (1988); <i>Nocula v. UGS</i>
<i>Corp.</i>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X18LKA4003?jcsearch=520%20f%203d%20719&amp;summary=yes#jcite">520 F.3d 719</a>, <a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X18LKA4003?jcsearch=520%20f%203d%20719&amp;summary=yes#jcite">725</a> (7th Cir.2008).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> Local 331 claims that the TPP Complaint "alleged with requisite
specificity that [Local 331] paid for Intron Franchise Drugs <i>like</i> Rebetol."
(Local 331 Reply at 9) (emphasis added). However, Local 331 does not cite
any portion of the TPP Complaint that states that Local 331 paid for any
Intron Franchise Drugs other than two Rebetol prescriptions. (<i>See</i> Local
<a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/1?citation=331%20bankruptcy%2015&amp;summary=yes#jcite">331 B.R. at 15</a>, citing &para; 19, 20, 21, 117, 127, 128).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> The District Court also held that the failure to allege an
injury-in-fact traceable to the alleged misconduct compelled the conclusion
that the TPP Plaintiffs lacked standing to assert the common law tort claims
of interference with contractual relations and unjust enrichment. We concur.
Accordingly, there is no need to address the question of whether Local 331
alleged viable claims for interference with contractual relations or unjust
enrichment.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> The District Court observed an apparent inconsistency in the MAC
regarding which drugs Dr. Willis decided not to prescribe in 1999 &mdash; Intron-A
and Rebetol, according to introductory parts of the MAC &mdash; and the drugs he
decided to prescribe in 2001 &mdash; Rebetol and PEG-Intron. (MAC &para; 23.) The Court
drew the "reasonable inference that the treatment discussed in 1999 involved
Rebetol and/or Intron-A, but not PEG-Intron" based on other information in
the MAC. It also stated: "despite the [MAC's] assertion that the 'same
drugs' that Dr. Willis had rejected as unsuited to Montgomery's condition in
1999 were under consideration in 2001, the records attached to the [MAC] and
specifically referenced in paragraph 29 state that Dr. Willis recommended in
2001 that Montgomery receive . . . PEG-Intron, not Intron A." (A. 109-110.)
</p></div>
<!--BBLS DD 1709411139587-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HO0DG003/history">Direct History (4)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HO0DG003/analysis">Case Analysis (38)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HO0DG003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
36
</span>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/distinguished.png'>
<div class='citation distinguished icon printHide' title='Distinguished'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HO0DG003/analysis?analysis=distinguished'>
Distinguished
</a>
<span class='citationNumberLabel'>
2
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Order Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1Q6LCI5KF82">10-03046 (3d Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/document/X1Q6LCI5KFO2">10-03047 (3d Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Constitutional Law</div><div class='facetItemLabel'>Torts</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/3de4ccbf5d4b435f76622fdd483573fe/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "3de4ccbf5d4b435f76622fdd483573fe";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY3a03c5&previousPageId=&previousActivityInstanceId=ENTITYe77d7a&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:46:18-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HO0DG003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYe77d7a&previousPageId=&previousActivityInstanceId=ENTITY20a90b&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:46:12-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1HO0DG003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HO0DG003";
$('#page_loader').show().spin();
JUDGE_IDS=["2445371","3028126"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
